Clinical-Stage company Heptares Announces Positive Results from Early-Stage Dementia Trial

Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for patients with cognitive impairment due to dementia and schizophrenia. During the Phase 1b study, 28 healthy elderly subjects were given different doses of HTL9936,  to test the effect of drug on measures of brain activity

Continue Reading